This page summarises and signposts to medicine related guidance we’re aware of from professional and government bodies relating to coronavirus and paediatric and neonatal medicine.
This page has been put together rapidly in relation to the COVID-19 pandemic.
Whilst we have tried to ensure that the information on this page is complete, please report a concern if you feel anything is omitted or inaccurate.
To see our professional guidance summaries for other clinical areas, click here
Advice in this area includes:
NHS England/NHS Improvement: Management of paediatric patients
Last updated 16 March 20
- This guidance sets out some principles to ensure that essential paediatric care continues with the minimum burden on the NHS during the coronavirus pandemic.
- It includes guidance on sharing information and collecting data.
- Recommendations are also given regarding emergency paediatric surgical services and service reconfiguration of paediatric intensive care units to meet adult demand.
NHS England/NHS Improvement: Management of paediatric critical care patients
Last updated 26 March 20
- This clinical and operational guidance is for paediatric intensive care units (PICUs; level 3) and paediatric high-dependency units (HDUs; level 2). It is also relevant to children’s wards with high dependency capabilities (level 1).
- Specific recommendations are given around a range of operational issues including supply and availability of oxygen and critical care medicines. Other recommendations include issues around staffing, communication, ventilators, and imaging.
NICE: COVID-19 rapid guideline: children and young people who are immunocompromised
Last updated 14 August 2020
- The purpose of this guideline is to maximise the safety of children and young people who are immunocompromised during the COVID-19 pandemic.
- It provides generalised guidance and advice for consideration.
- This includes managing the underlying condition, including advice on face to face appointments when these are deemed necessary, and what to consider before starting medicines which affect the immune system.
- For those who need to continue such treatments, principles to consider adopting in order to minimise risk, such as route of administration and frequency of monitoring are also provided.
- Guidance is also given around managing the underlying condition if a patient is known, or suspected to have, COVID-19 infection.
Royal College of Paediatrics and Child Health: COVID-19
- There is a dedicated section on the website which includes a range of guidance on paediatric services and settings, including neonatal, community, and acute and emergency settings.
- Summaries of research and clinical data are also included.
- A guideline regarding use of anti-inflammatory medicines to manage COVID-19 symptoms is also available.
- Guidance is also available for parents.
Royal College of Paediatrics and Child Health: Guidance—Paediatric multisystem inflammatory syndrome temporally associated with COVID-19
Last updated 1 May 2020
- In the last two months a small number of children have been identified who develop a significant systemic inflammatory response in association with COVID-19.
- Early recognition by paediatricians and specialist referral including to critical care is essential.
- This guidance raises awareness and gives management advice to clinicians. It has been developed after expert review of the cases.
- A case definition is given, and includes clinical and laboratory features additionally listed in Appendix 1.
- An approach to clinical management is also outlined giving details on early medical management and monitoring.
- General principles regarding treatments to consider include: local policies on COVID-19 management and antimicrobial treatments, antiviral therapy, immunomodulatory therapy, IVIG and/or aspirin, and potential recruitment into research studies.
- An Appendix is also included regarding relevant clinical trials which are recruiting or launching soon.
Neonatal and Paediatric Pharmacists Group: Position statement
Last updated 2 April 20
- The position statement confirms that medications which could potentially be used to treat COVID-19 must only be used within a clinical trial or compassionate use program.
- It also outlines what information to expect from the NPPG over the coming weeks.
- Signposts are also given to other useful guidance currently published.
Administration update (28 August 2020): Administrative amendments made as indicated by red text.